Skip to Content

Sutent Approval History

Sutent (sunitinib malate) is an oral multi-kinase inhibitor indicated for the treatment of gastrointestinal stromal tumors, advanced renal cell carcinoma (RCC), adjuvant treatment of patients at high risk of recurrent RCC following nephrectomy, and the treatment of pancreatic neuroendocrine tumors.

Development History and FDA Approval Process for Sutent

Nov 16, 2017Approval FDA Approves Sutent (sunitinib malate) for Adjuvant Treatment of Adult Patients at High Risk of Recurrent Renal Cell Carcinoma
May 20, 2011Approval FDA Approves Sutent for Rare Type of Pancreatic Cancer
Jan 26, 2006Approval FDA Approves Sutent for Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma
Aug 10, 2005Pfizer Submits New Drug Application for Sutent to FDA

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.